Tirzepatide Delivers 20% to 25% Weight Loss as Semaglutide Averages 15%
Updated
Updated · Kettering Health · Aug 17
Tirzepatide Delivers 20% to 25% Weight Loss as Semaglutide Averages 15%
3 articles · Updated · Kettering Health · Aug 17
Summary
Clinical trials showed tirzepatide users lost about 20% to 25% of body weight over time, versus roughly 15% for semaglutide over about 18 months.
Both approved obesity drugs curb appetite, slow stomach emptying and improve blood-sugar control; tirzepatide may produce greater losses because it targets two hormones—GLP-1 and GIP—while semaglutide targets GLP-1 alone.
BMI thresholds limit use to adults at 30 or higher, or 27 with at least one weight-related condition, reflecting their role when lifestyle changes alone are not enough.
Common side effects include nausea, vomiting, diarrhea, constipation and bloating, while rarer serious risks include gallstones, low blood sugar, dehydration and pancreatitis.
Long-term use may be needed to maintain weight loss, and people with a personal or family history of medullary thyroid cancer or MEN2 should avoid the medications.
If stopping these medications causes rapid weight regain, are we trading a lifestyle disease for a lifelong dependence on pharmaceutical subscriptions?
With experimental triple-agonist drugs promising up to 30% weight loss by 2027, will traditional bariatric surgery soon become completely obsolete?
As unregulated compounded injections cause hospitalizations, will the massive 2026 rollout of daily oral weight-loss tablets finally crush the dangerous black market?